JP2024536879A - タクロリムスを含む薬学的製剤、その調製のための方法、および使用 - Google Patents

タクロリムスを含む薬学的製剤、その調製のための方法、および使用 Download PDF

Info

Publication number
JP2024536879A
JP2024536879A JP2024519103A JP2024519103A JP2024536879A JP 2024536879 A JP2024536879 A JP 2024536879A JP 2024519103 A JP2024519103 A JP 2024519103A JP 2024519103 A JP2024519103 A JP 2024519103A JP 2024536879 A JP2024536879 A JP 2024536879A
Authority
JP
Japan
Prior art keywords
microparticles
polymer
pharmaceutical formulation
poly
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536879A5 (https=
Inventor
エバンゲロス カラバス，
エフシミオス クトリス，
リダ カランツィ，
ソティリア チャイティドゥ，
ニコス レモナキス，
アンナ パパダキ，
ヴィンセント ブリューデス，
アルテミス カレジ，
アタナシオス カツェニス，
カテリーナ コッティ，
Original Assignee
ファーマシェン エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20210100639A external-priority patent/GR1010308B/el
Priority claimed from GB2116138.5A external-priority patent/GB2612779A/en
Application filed by ファーマシェン エス．エー． filed Critical ファーマシェン エス．エー．
Publication of JP2024536879A publication Critical patent/JP2024536879A/ja
Publication of JP2024536879A5 publication Critical patent/JP2024536879A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024519103A 2021-09-27 2022-09-27 タクロリムスを含む薬学的製剤、その調製のための方法、および使用 Pending JP2024536879A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GR20210100639A GR1010308B (el) 2021-09-27 2021-09-27 Φαρμακευτικο σκευασμα που περιλαμβανει τακρολιμους, μεθοδος για την παρασκευη και χρηση αυτου
GR20210100639 2021-09-27
GB2116138.5A GB2612779A (en) 2021-11-10 2021-11-10 Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
GB2116138.5 2021-11-10
PCT/EP2022/025445 WO2023046321A1 (en) 2021-09-27 2022-09-27 Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use

Publications (2)

Publication Number Publication Date
JP2024536879A true JP2024536879A (ja) 2024-10-08
JP2024536879A5 JP2024536879A5 (https=) 2025-09-29

Family

ID=83902713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519103A Pending JP2024536879A (ja) 2021-09-27 2022-09-27 タクロリムスを含む薬学的製剤、その調製のための方法、および使用

Country Status (10)

Country Link
US (1) US20250319028A1 (https=)
EP (1) EP4440550A1 (https=)
JP (1) JP2024536879A (https=)
KR (1) KR20240060874A (https=)
AU (1) AU2022351126A1 (https=)
CA (1) CA3233139A1 (https=)
CO (1) CO2024005380A2 (https=)
MX (1) MX2024003886A (https=)
WO (1) WO2023046321A1 (https=)
ZA (1) ZA202403104B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120000593B (zh) * 2024-12-27 2026-03-20 广东药科大学 一种他克莫司微晶及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
MX2007011494A (es) 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
WO2017173534A1 (en) * 2016-04-05 2017-10-12 The Hospital For Sick Children System for delivery of fk506 for enhancing nerve regeneration

Also Published As

Publication number Publication date
CO2024005380A2 (es) 2024-05-30
MX2024003886A (es) 2024-07-10
WO2023046321A1 (en) 2023-03-30
WO2023046321A8 (en) 2024-05-30
AU2022351126A1 (en) 2024-05-09
EP4440550A1 (en) 2024-10-09
CA3233139A1 (en) 2023-03-30
KR20240060874A (ko) 2024-05-08
US20250319028A1 (en) 2025-10-16
ZA202403104B (en) 2025-01-29

Similar Documents

Publication Publication Date Title
US10568860B2 (en) Pharmaceutical composition containing statin-encapsulated nanoparticle
Wischke et al. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide
JP2004514734A (ja) 疎水性薬物の徐放性デリバリー用組成物及びその製造方法
KR20040030869A (ko) 안구주위 또는 결막하부 투여를 위한 안과용 데포 제제
JP5507447B2 (ja) 微粒子中にソマトスタチン誘導体を含む持続放出組成物
KR20130024986A (ko) 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
JP2016527308A (ja) エンテカビル微小球及びこれを含む非経口投与用医薬組成物
CN102245210A (zh) 有恒定高暴露水平的奥曲肽贮库制剂
CN103893129B (zh) 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法
EP1679065A1 (en) Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20250319028A1 (en) Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use
CN103948911A (zh) 一种棘白菌素类抗真菌药物缓释微球制剂及其制备方法
AU2007263004A1 (en) Sustained release formulations of aromatase inhibitors
CN118043036A (zh) 包含他克莫司的药物制剂、其制备方法和用途
GB2612779A (en) Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
HK40104581A (zh) 包含他克莫司的药物制剂、其制备方法和用途
US20190117573A1 (en) Composition and method of preparation of risperidone extended release preparation
CN1969820A (zh) 抗癌药物组合物
CN118267362A (zh) 一种爱地那非长效缓释注射剂及其制备方法和用途
WO2025096848A1 (en) Ph-controlled biodegradable polymeric particles for sustained release of positively charged species
EP3372224A1 (en) New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
CN1969827A (zh) 含埃坡霉素和间质水解剂的抗实体肿瘤组合物
CN1969823A (zh) 一种含氟尿嘧啶及其增效剂的缓释剂
HK1185560B (en) Risperidone sustained release microsphere composition
HK1185560A1 (en) Risperidone sustained release microsphere composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250918